Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-05-09
2010-11-09
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S287000, C549S471000
Reexamination Certificate
active
07829574
ABSTRACT:
Substituted quinazoline compounds of the following formula:wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and X are defined herein. It also discloses a pharmaceutical composition containing one of these compounds.
REFERENCES:
patent: 5457105 (1995-10-01), Barker
patent: 6235741 (2001-05-01), Bilodeau et al.
patent: 6723726 (2004-04-01), Cockerill et al.
patent: 2003/0149041 (2003-08-01), Erickson et al.
patent: 2004/0092750 (2004-05-01), Hasegawa et al.
patent: 2005/0137395 (2005-06-01), Hong et al.
patent: 2006/0247262 (2006-11-01), Baenteli et al.
patent: 2007/0208056 (2007-09-01), Carter et al.
patent: 2008/0033000 (2008-02-01), Chang
patent: 1265874 (2002-12-01), None
patent: 1 154 774 (2005-06-01), None
patent: 1154774 (2005-06-01), None
patent: 535109 (2006-05-01), None
patent: WO 02/30924 (2002-04-01), None
patent: 03/063794 (2003-08-01), None
patent: 2004/014382 (2004-02-01), None
patent: 2005/009978 (2005-02-01), None
patent: 2005/026158 (2005-03-01), None
patent: 2005/063739 (2005-07-01), None
patent: WO 2005/063739 (2005-07-01), None
patent: 2006/071017 (2006-07-01), None
patent: 2006/071079 (2006-07-01), None
patent: 2006/138304 (2006-12-01), None
patent: WO 2007/066181 (2007-06-01), None
patent: WO 2009/036055 (2009-03-01), None
Jordan, V. C. Nature Reviews: Drug Discovery, 2, 2003, p. 205.
Dörwald, F. Zaragoza. Side Reactions in Organic Synthesis: A Guide to Successful Synthesis Design, Weinheim: WILEY-VCH Verlag GmbH & Co. KGaA, 2005, Preface.
Verma et al. “Substituted Aminobenzimidazole Pyrimidines as Cyclin-Dependent Kinase Inhibitors” Bioorganic & medicinal Chemistry Letters 15 92005) 1973-1977, 5 pages.
Zhang et al. “Discovery of EGFR Selective 4,6-Disubstituted Pyrimidines from a Combinatorial Kinase-Directed Heterocycle Library,” J.Am. Chem. Soc. 2006, 128, 2182-2183.
Harris et al., “Three-point variation of a gefinitib quinazoline core,”Tetrahedron Letters, 50:1600-1602 (2009).
Nakamura et al., “KRN951, a Highly Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Has Antitumor Activities and Affects Functional Vascular Properties,”Cancer Research, 66:9134-9142 (2006).
Cui Yumin
Duan Jifeng
Ren Yongxin
Su Wei-Guo
Yan Xiaoqiang
Finnegan Henderson Farabow Garrett & Dunner LLP
Hutchison MediPharma Enterprises Limited
Willis Douglas M
Wilson James O
LandOfFree
Substituted quinazoline compounds and their use in treating... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted quinazoline compounds and their use in treating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted quinazoline compounds and their use in treating... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4200713